secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001213900-25-118969
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX discontinues Phase 2b CF trial of BX004, cuts workforce, explores strategic alternatives
--------------------------------------------------------------------------------

- Independent DMC had recommended continuing Study with adjusted dosing, but company cites insufficient resources to execute alternative strategy.
- Significant workforce reduction being implemented as part of cost-cutting measures.
- BiomX will focus on advancing BX011 for diabetic foot infections, subject to financial resource availability.
- Company is reviewing strategic alternatives to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025118969/0001213900-25-118969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025118969/ea0268807-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-118969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer